ResearcherUniversity of BolognaActive in the last 2 years

Giovanni Ferrandi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0004-1656-2961; OpenAlex author ID A5099839524. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 8

Papers, trials and grants by year

2025: 1 paper · 2026: 1 paper

Papers 2

Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a Novel Phenyl Furan-Quinoline-Carboxylic A… Co-author DOI 10.1021/acsmedchemlett.5c00711 ↗
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity. Co-author DOI 10.1038/s41420-025-02382-3 ↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Greta Bagnolini · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711 ↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Marinella Roberti · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711 ↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Stefania Girotto · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711 ↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Andrea Cavalli · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711 ↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Mirco Masi · 2 shared papers, 2025–2026 · strength 0.44
- Paper Targeting RAD51-BRCA2 Interaction to Enhance Synthetic Lethality with Olaparib in Pancreatic Cancer: Development of a N… DOI 10.1021/acsmedchemlett.5c00711 ↗
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Naomi Walsh · 1 shared paper, 2025 · strength 0.18
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Samuel Harry Myers · 1 shared paper, 2025 · strength 0.18
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗
Shannon R. Nelson · 1 shared paper, 2025 · strength 0.18
- Paper Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential ac… DOI 10.1038/s41420-025-02382-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.